JNJ-7925476

Last updated
JNJ-7925476
Johnson123.png
Identifiers
  • (6S,10bR)-6-(4-Ethynylphenyl)-1H,2H,3H,5H,6H,10bH-pyrrolo[2,1-a]isoquinoline
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C20H19N
Molar mass 273.379 g·mol−1
3D model (JSmol)
  • C#CC1=CC=C(C=C1)[C@@H]2CN3CCC[C@@H]3C4=CC=CC=C24
  • InChI=1S/C20H19N/c1-2-15-9-11-16(12-10-15)19-14-21-13-5-8-20(21)18-7-4-3-6-17(18)19/h1,3-4,6-7,9-12,19-20H,5,8,13-14H2/t19-,20+/m0/s1
  • Key:YPFCCQUUZJDQAM-VQTJNVASSA-N
   (verify)

JNJ-7925476 is a triple reuptake inhibitor antidepressant discovered by Johnson & Johnson, [1] but never marketed.

Contents

These molecules were first prepared by Bruce E. Maryanoff and coworkers during the late 1970s–1980s. [2] [3] [4] The structure is a pyrrolo isoquinoline core, with an overlaid benzhydryl motif.

Incorporating the pyrrolidino ring onto the tetrahydroisoquinoline scaffolding markedly improves potency, although this only works for one of the available stereoisomers. JNJ-7925476 is a racemic preparation of the more potent diastereomer. Of these enantiomers, the eutomer is the (6R,10bS) stereoisomer, known as JNJ-39836966, and the distomer, (6S,10bR), is JNJ-39836732

There is some confusion over the nomenclature and cis/trans isomeric relationship at the piperidine ring. The compounds as depicted have the carbon of the pyrrolidine carbon and the phenyl cis, but Maryanoff and coworkers are of the opinion that the compound is trans. [1] (see abstract)

The reason for this is not known because it was referred to as "cis" in earlier reports, and then later reassigned.

In-vitro characterization

Ki values (nM) for JNJ-7925476 and its constituent enantiomers (JNJ-39836966 and JNJ-39836732)

JNJrSERThSERThDAThNET
79254760.40.95.216.6
398369660.330.271.615.8
3983673217.04.174.3227

In vitro, JNJ-7925476 is ~18-fold selective for the hSERT (0.9 nM) over the hNET (16.6 nM).

Ex vivo transporter occupancy of JNJ-7925476 (in rat brain) followed the ordering priority: NET > SERT > DAT.

This is consistent with the results cited earlier for rat brains (see SAR table dated 1987).

However, there is relatively poor correlation between the in vitro data presented for rats brains vs what was reported at the human transporters.

μ-Dialysis

Elevations in extracellular DA in vivo was higher than expected on the basis of the in vitro transporter affinities.

The authors speculate that this could be because in the PFC where DATs are low in number, DA is predominantly transported via the NET. [5]

Ex vivo occupancy of the DAT was much lower (<50%) at this dose though, whereas the NET and SERT were similar (~90%).

It took a much higher dose (c.f. 10 mg/kg) for the DAT occupancy to approach the same as the NET and SERT (i.e. saturation).

At saturation, the elevation in synaptic DA was extremely prolific (15 × baseline), whereas SER and NE was ≈ ½ this amount (i.e. 750%).

Pyrroloisoquinolines structure activity relationships

3d structure, Y = OMe Maryanoff's antidepressant number 12B (1987) with tube model.png
3d structure, Y = OMe
Pyrroloisoquinoline.png
XYVWMA (mg/kg)ptosis (mg/kg)DA (nM)NE (nM)5-HT (nM)
HHHH0.34 (0.59)0.07 (0.05)11.3 (4.4)0.60 (0.37)23.5 (12.4)
HHOMeOMe15.13.815.053.71540
HHOHOH0.870.5343.510.5124
OMeHHH0.270.035.20.791.7
OHHHH0.400.095.10.743.2
HOMeHH~0.20.0715.80.657.2
HOHHH>100.1110.10.8524.6
HHHOMeno datano data2.82.24.5
OMeOMeHH2.00.1371.93.418.1
OHOHHH0.190.1110.10.8133.1
ClHHH0.550.341.70.161.5
HClHH~0.1<0.12.50.457.3
ClHHCl37.4~43.23.22.9
ClClHH0.390.140.990.681.8
FHHH~0.2~0.28.41.48.5
FHHF>300.057.70.554.4
NH2HHH~0.2~0.010.860.2044
SMeHHH>30 (no data)0.30 (no data)41.2 (23.5)3.0 (1.8)0.62 (0.39)
EthynylHHH~0.5~0.52.60.941.0
diclofensine10.98.810.3
WIN-25978 7.241.1879

This is a collection of all of the analogs that had favorable biological activity or an interesting substitution pattern.

All compounds are racemic preparations with the exception that brackets are for pure (+) enantiomer.

Para-Fluoro

JNJ-7925476 according to AK Dutta JNJ-7925476 according to AK Dutta.png
JNJ-7925476 according to AK Dutta

AK Dutta, et al. draws JNJ-7925476 with a fluorine in lieu of an ethynyl, without specifying the exact stereochemistry, e.g. [6] [7] [8] [9]

For JNJ-7925476 itself, the Ethynyl group is made from the p-iodo group (i.e. PC9951513), although no actual attempt was made by any of the authors to characterize this into the SAR list of quantitative data. Like RTI-55 it was made prepared with radiolabelled iodine is an excellent way to scan the brain using positron emission tomography.

Aloke Dutta's compound can also be made in radiolabelled form, ala Flubatine.

Instead of alkyne, one can also replace the halogen with cyanide (nitrile), ala citalopram. Although not inputted into the tablet above, this was another one of the McNeal analogues.

Ring size structure activity relationships

Expanding the ring size from pyrrolidino to piperidinyl resulted in compounds that were impotent, although contracting the ring size from 5 → 4 did not have negative repercussions on the resultant potency.

Chemistry

The N-acyliminium cyclization route; and the mandelic acid and styrene oxide route were employed for most of the target compounds.

Pyrroloisoquinoline Synthesis Pyrroloisoquinoline Synthesis.png
Pyrroloisoquinoline Synthesis

The SS/RR diastereomers as the principle products if one follows the above steps. [10] [11]

It is possible to epimerize the product to the desired RS/SR diastereomers, but the equilibrium is only 50/50.

Hence, alternative synthetic methods needed to be sought to obtain the desired isomer/s in diastereochemical excess.

If instead of an "aryl" group, a tert-butyl or a cyclohexyl was used, then it was possible to alter the stereochemical discourse of the reaction. [12]

Stereoselective reaction

Pyrroloisoquinoline revised synthesis.svg

Hydrogenation of an appropriately positioned olefin might be expected to work. [14] [15]

But the ketone cannot be reduced to an alcohol because it is part of an amide.

Related Research Articles

<span class="mw-page-title-main">Monoamine transporter</span> Proteins that function as integral plasma-membrane transporters

Monoamine transporters (MATs) are proteins that function as integral plasma-membrane transporters to regulate concentrations of extracellular monoamine neurotransmitters. The three major classes are serotonin transporters (SERTs), dopamine transporters (DATs), and norepinephrine transporters (NETs) and are responsible for the reuptake of their associated amine neurotransmitters. MATs are located just outside the synaptic cleft (peri-synaptically), transporting monoamine transmitter overflow from the synaptic cleft back to the cytoplasm of the pre-synaptic neuron. MAT regulation generally occurs through protein phosphorylation and post-translational modification. Due to their significance in neuronal signaling, MATs are commonly associated with drugs used to treat mental disorders as well as recreational drugs. Compounds targeting MATs range from medications such as the wide variety of tricyclic antidepressants, selective serotonin reuptake inhibitors such as fluoxetine (Prozac) to stimulant medications such as methylphenidate (Ritalin) and amphetamine in its many forms and derivatives methamphetamine (Desoxyn) and lisdexamfetamine (Vyvanse). Furthermore, drugs such as MDMA and natural alkaloids such as cocaine exert their effects in part by their interaction with MATs, by blocking the transporters from mopping up dopamine, serotonin, and other neurotransmitters from the synapse.

<span class="mw-page-title-main">Phenyltropane</span> Class of chemical compounds

Phenyltropanes (PTs) were originally developed to reduce cocaine addiction and dependency. In general these compounds act as inhibitors of the plasmalemmal monoamine reuptake transporters. This research has spanned beyond the last couple decades, and has picked up its pace in recent times, creating numerous phenyltropanes as research into cocaine analogues garners interest to treat addiction.

<span class="mw-page-title-main">(+)-CPCA</span> Stimulant drug

(+)-CPCA is a stimulant drug similar in structure to pethidine and to RTI-31, but nocaine is lacking the two-carbon bridge of RTI-31's tropane skeleton. This compound was first developed as a substitute agent for cocaine.

A serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), also known as a triple reuptake inhibitor (TRI), is a type of drug that acts as a combined reuptake inhibitor of the monoamine neurotransmitters serotonin, norepinephrine, and dopamine. It does this by concomitantly inhibiting the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT), respectively. Inhibition of the reuptake of these neurotransmitters increases their extracellular concentrations and, therefore, results in an increase in serotonergic, adrenergic, and dopaminergic neurotransmission. The naturally-occurring and potent SNDRI cocaine is widely used recreationally and often illegally for the euphoric effects it produces.

<span class="mw-page-title-main">Indatraline</span> Chemical compound

Indatraline hydrochloride is an antidepressive agent and non-selective monoamine transporter inhibitor that blocks the reuptake of dopamine, norepinephrine, and serotonin with similar efficacy to cocaine. This compound may be used to treat cocaine addictions as its effects have a slower onset and a longer duration than those of cocaine. Lu 19-005 has been shown to block the action of methamphetamine and MDMA in laboratory experiments.

<span class="mw-page-title-main">Mazindol</span> Stimulant drug and appetite suppressant

Mazindol is a stimulant drug which is used as an appetite suppressant. It was developed by Sandoz-Wander in the 1960s.

<span class="mw-page-title-main">Nisoxetine</span> Chemical compound

Nisoxetine, originally synthesized in the Lilly research laboratories during the early 1970s, is a potent and selective inhibitor for the reuptake of norepinephrine (noradrenaline) into synapses. It currently has no clinical applications in humans, although it was originally researched as an antidepressant. Nisoxetine is now widely used in scientific research as a standard selective norepinephrine reuptake inhibitor. It has been used to research obesity and energy balance, and exerts some local analgesia effects.

<span class="mw-page-title-main">Ciclazindol</span> Chemical compound

Ciclazindol (WY-23409) is an antidepressant and anorectic drug of the tetracyclic chemical class that was developed in the mid to late 1970s, but was never marketed. It acts as a norepinephrine reuptake inhibitor, and to a lesser extent as a dopamine reuptake inhibitor. Ciclazindol has no effects on the SERT, 5-HT receptors, mACh receptors, or α-adrenergic receptors, and has only weak affinity for the H1 receptor. As suggested by its local anesthetic properties, ciclazindol may also inhibit sodium channels. It is known to block potassium channels as well.

<span class="mw-page-title-main">Tametraline</span> Chemical compound

Tametraline (CP-24,441) is the parent of a series of chemical compounds investigated at Pfizer that eventually led to the development of sertraline (CP-51,974-1).

<span class="mw-page-title-main">Plasma membrane monoamine transporter</span> Protein-coding gene in the species Homo sapiens

The plasma membrane monoamine transporter (PMAT) is a low-affinity monoamine transporter protein which in humans is encoded by the SLC29A4 gene. It is known alternatively as the human equilibrative nucleoside transporter-4 (hENT4). It was discovered in 2004 and has been identified as a potential alternate target for treating various conditions.

<span class="mw-page-title-main">RTI-31</span> Chemical compound

(–)-2β-Carbomethoxy-3β-(4'-chlorophenyl)tropane (RTI-4229-31) is a synthetic analog of cocaine that acts as a stimulant. Semi-synthesis of this compound is dependent upon the availability of cocaine starting material. According to the article, RTI-31 is 64 times the strength of cocaine in terms of its potency to elicit self-administration in monkeys. WIN 35428 was 6 times weaker than RTI-31, whereas RTI-51 was 2.6 times weaker than RTI-31.

<span class="mw-page-title-main">Norepinephrine–dopamine reuptake inhibitor</span> Drug that inhibits the reuptake of norepinephrine and dopamine

A norepinephrine–dopamine reuptake inhibitor (NDRI) is a drug used for the treatment of clinical depression, attention deficit hyperactivity disorder (ADHD), narcolepsy, and the management of Parkinson's disease. The drug acts as a reuptake inhibitor for the neurotransmitters norepinephrine and dopamine by blocking the action of the norepinephrine transporter (NET) and the dopamine transporter (DAT), respectively. This in turn leads to increased extracellular concentrations of both norepinephrine and dopamine and, therefore, an increase in adrenergic and dopaminergic neurotransmission.

<span class="mw-page-title-main">JZ-IV-10</span> Chemical compound

JZ-IV-10 is a piperidine derivative related to cocaine which acts as a highly potent serotonin–norepinephrine–dopamine reuptake inhibitor. The eugeroic modafinil was used as a lead to fuel this compound's discovery.

<span class="mw-page-title-main">RTI-83</span> Chemical compound

RTI-83 is a phenyltropane derivative which represents a rare example of an SDRI or serotonin-dopamine reuptake inhibitor, a drug which inhibits the reuptake of the neurotransmitters serotonin and dopamine, while having little or no effect on the reuptake of the related neurotransmitter noradrenaline. With a binding affinity (Ki) of 55 nM at DAT and 28.4 nM at SERT but only 4030 nM at NET, RTI-83 has reasonable selectivity for DAT/SERT over NET

<span class="mw-page-title-main">Serotonin–dopamine reuptake inhibitor</span> Class of drug

A serotonin–dopamine reuptake inhibitor (SDRI) is a type of drug which acts as a reuptake inhibitor of the monoamine neurotransmitters serotonin and dopamine by blocking the actions of the serotonin transporter (SERT) and dopamine transporter (DAT), respectively. This in turn leads to increased extracellular concentrations of serotonin and dopamine, and, therefore, an increase in serotonergic and dopaminergic neurotransmission.

A monoamine reuptake inhibitor (MRI) is a drug that acts as a reuptake inhibitor of one or more of the three major monoamine neurotransmitters serotonin, norepinephrine, and dopamine by blocking the action of one or more of the respective monoamine transporters (MATs), which include the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT). This in turn results in an increase in the synaptic concentrations of one or more of these neurotransmitters and therefore an increase in monoaminergic neurotransmission.

<span class="mw-page-title-main">WY-46824</span> Chemical compound

WY-46824 is a norepinephrine-dopamine reuptake inhibitor related to venlafaxine that was disclosed by Paige Mahaney, et al. of Wyeth in 2008. The compound actually appears in an article a year earlier in 2007 but is not the main focus of the work. It has NET binding of 46 nM, DAT = 58 nM and SERT = 18795 nM. The racemic compound was resolved into its constituent enantiomers, and the (S) enantiomer is the more active one. The N-desmethyl derivative shows similar activity.

Selective serotonin reuptake inhibitors, or serotonin-specific re-uptake inhibitor (SSRIs), are a class of chemical compounds that have application as antidepressants and in the treatment of depression and other psychiatric disorders. SSRIs are therapeutically useful in the treatment of panic disorder (PD), posttraumatic stress disorder (PTSD), social anxiety disorder, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), and anorexia. There is also clinical evidence of the value of SSRIs in the treatment of the symptoms of schizophrenia and their ability to prevent cardiovascular diseases.

References

  1. 1 2 Aluisio L, Lord B, Barbier AJ, Fraser IC, Wilson SJ, Boggs J, et al. (June 2008). "In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor". European Journal of Pharmacology. 587 (1–3): 141–6. doi:10.1016/j.ejphar.2008.04.008. PMID   18499098.
  2. ↑ Maryanoff BE, McComsey DF, Castanzo MJ, Setler PE, Gardocki JF, Shank RP, Schneider CR (August 1984). "Pyrroloisoquinoline antidepressants. Potent, enantioselective inhibition of tetrabenazine-induced ptosis and neuronal uptake of norepinephrine, dopamine, and serotonin". Journal of Medicinal Chemistry. 27 (8): 943–6. doi:10.1021/jm00374a001. PMID   6747993.
  3. ↑ Maryanoff BE, McComsey DF, Gardocki JF, Shank RP, Costanzo MJ, Nortey SO, et al. (August 1987). "Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships". Journal of Medicinal Chemistry. 30 (8): 1433–54. doi:10.1021/jm00391a028. PMID   3039136.
  4. ↑ Maryanoff BE, Vaught JL, Shank RP, McComsey DF, Costanzo MJ, Nortey SO (October 1990). "Pyrroloisoquinoline antidepressants. 3. A focus on serotonin". Journal of Medicinal Chemistry. 33 (10): 2793–7. doi:10.1021/jm00172a018. PMID   2213832.
  5. ↑ Morón JA, Brockington A, Wise RA, Rocha BA, Hope BT (January 2002). "Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines". The Journal of Neuroscience. 22 (2): 389–95. doi:10.1523/JNEUROSCI.22-02-00389.2002. PMC   6758674 . PMID   11784783.
  6. ↑ Dutta AK, Santra S, Sharma H, Voshavar C, Xu L, Mabrouk O, et al. (2014). "Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters". PLOS ONE. 9 (11): e113420. Bibcode:2014PLoSO...9k3420D. doi: 10.1371/journal.pone.0113420 . PMC   4245125 . PMID   25427177.
  7. ↑ Santra S, Gogoi S, Gopishetty B, Antonio T, Zhen J, Reith ME, Dutta AK (December 2012). "Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressants". ChemMedChem. 7 (12): 2093–100. doi:10.1002/cmdc.201200352. PMC   3733990 . PMID   23060293.
  8. ↑ Santra S, Sharma H, Vedachalam S, Antonio T, Reith M, Dutta A (February 2015). "Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template". Bioorganic & Medicinal Chemistry. 23 (4): 821–8. doi:10.1016/j.bmc.2014.12.040. PMC   4318756 . PMID   25593099.
  9. ↑ Gopishetty B, Hazeldine S, Santra S, Johnson M, Modi G, Ali S, et al. (April 2011). "Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents". Journal of Medicinal Chemistry. 54 (8): 2924–32. doi:10.1021/jm200020a. PMC   3085959 . PMID   21446715.
  10. ↑ Maryanoff B (1979). "Iminium ion cyclizations. Highly stereoselective synthesis of substituted tetrahydroisoquinoline derivatives". Tetrahedron Letters. 20 (40): 3797–3800. doi:10.1016/S0040-4039(01)95527-3.
  11. ↑ Maryanoff BE, Mccomsey DF, Duhl-Emswiler BA (1983). "Stereochemistry of intramolecular amidoalkylation reactions in the synthesis of polycyclic isoquinoline derivatives". The Journal of Organic Chemistry. 48 (25): 5062–5074. doi:10.1021/jo00173a053.
  12. ↑ Maryanoff BE, Mccomsey DF, Almond HR, Mutter MS, Bemis GW, Whittle RR, Olofson RA (1986). "Dramatic reversal of diastereoselectivity in an N-acyliminium ion cyclization leading to hexahydropyrrolo[2,1-a]isoquinolines. A case of competing steric interactions". The Journal of Organic Chemistry. 51 (8): 1341–1346. doi:10.1021/jo00358a034.
  13. U.S. patent 4,837,328
  14. ↑ Maryanoff BE, McComsey DF, Mutter MS, Sorgi KL, Maryanuff CA (1988). "Highly stereocontrolled proton transfer in an enammonium-iminium rearrangement. Mechanism of the stereoselective deoxygenation of 6-aryl-6-hydroxy-1,2,3,5,6,10b-hexahydropyrrolo[2.1-]isoquinolines with borane-thf in trifluoroacetic acid". Tetrahedron Letters. 29 (40): 5073–5076. doi:10.1016/S0040-4039(00)80682-6.
  15. ↑ McComsey DF, Maryanoff BE (August 2000). "3-Aza-cope rearrangement of quaternary N-allyl enammonium salts. Stereospecific 1,3 allyl migration from nitrogen to carbon on a tricyclic template". The Journal of Organic Chemistry. 65 (16): 4938–43. doi:10.1021/jo000363h. PMID   10956475.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.